Round 2 Overview
Focus for Round 2
The role of Queensland Genomics is to maximise the benefits presented by genomic medicine and more broadly precision medicine. Queensland Genomics brings together healthcare system innovation, medical and social research to enable the implementation of medical genomics into mainstream healthcare.
In Round 2, Queensland Genomics moves from its initial research, demonstration and discovery orientation in Round 1, to a focus on patient outcomes through:
Investing in genomics-based clinical implementation projects
Creating an incubation pipeline for future clinical implementation
Investing in clinical innovation projects to match future needs
Building the required capability and infrastructure in the health system.
The Round 2 investment decision making process is a project co-design process running from June 2018 – November 2018. Queensland Genomics is implementing an investment decision model for Round 2 Clinical Projects in which Queensland Genomics calls for Expressions of Interest (EOI) and works with applicants through a gate-based co-design process. The below image provides an overview of the gate process, which brings together the Round 2 clinical projects with the capability and infrastructure work program for 2019.
The following principles for Round 2 investment and decision making have been approved by Queensland Health.